- Ongoing, recruitingTherapeutic exploratory (Phase II)
KEYMAKER-U01 Substudy 1: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents with Pembrolizumab in Combination with Chemotherapy in Treatment-Naive Patients with Advanced Non-small Cell Lung Cancer (NSCLC)
This study is testing different new drug combinations with pembrolizumab and chemotherapy for people with advanced non-small cell lung cancer who haven't had treatment yet. It's looking at how well the new combinations shrink tumors and if they have side effects.
For: non-small cell lung cancerItaly · Hungary · Poland - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizuma Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02B
This study is looking at new treatments for melanoma, a type of skin cancer, that has not responded to previous therapies. Researchers want to see how safe these new treatments are, especially when given with or without a common cancer drug called pembrolizumab (Keytruda).
For: PD-1 refractory melanomaSpain · France · Greece - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1/2 Open-label, Rolling-arm, Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYMAKER-U02): Substudy 02A
This study is testing new combinations of medicines for advanced melanoma that hasn't responded to previous treatment. Researchers want to see if these new treatments are safe and if they can shrink tumours. It's for adults aged 18 and over.
For: PD-1 refractory melanomaFrance · Italy - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYMAKER-U02): Substudy 02C
This study is for people in the UK with advanced melanoma, a type of skin cancer. It's testing new ways to treat it, sometimes combined with an existing medicine called Pembrolizumab (Keytruda). The main goals are to see how safe the new treatments are and how well they work.
For: Stage IIIB or IIIC or IIID melanomaFrance · Italy